BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ito T, Hijioka S, Masui T, Kasajima A, Nakamoto Y, Kobayashi N, Komoto I, Hijioka M, Lee L, Igarashi H, Jensen RT, Imamura M. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 2017;52:9-18. [PMID: 27539256 DOI: 10.1007/s00535-016-1250-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bober B, Saracyn M, Zaręba K, Lubas A, Mazurkiewicz P, Wilińska E, Kamiński G. Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study. J Clin Med 2022;11:919. [PMID: 35207193 DOI: 10.3390/jcm11040919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol 2021;56:1033-44. [PMID: 34586495 DOI: 10.1007/s00535-021-01827-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
4 Kogami T, Iwai T, Kida M, Okuwaki K, Hasegawa R, Kurosu T, Watanabe M, Matsushita M, Imawari K, Adachi K, Tadehara M, Tamaki A, Imaizumi H, Koizumi W. A case of pancreatic neuroendocrine carcinoma with a favorable clinical response to pembrolizumab. Clin J Gastroenterol 2021;14:1804-10. [PMID: 34495482 DOI: 10.1007/s12328-021-01505-4] [Reference Citation Analysis]
5 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
6 Xu W, Zhang H, Feng G, Zheng Q, Shang R, Liu X. The value of MRI in identifying pancreatic neuroendocrine tumour G3 and carcinoma G3. Clin Radiol 2021;76:551.e1-9. [PMID: 33902887 DOI: 10.1016/j.crad.2021.02.031] [Reference Citation Analysis]
7 Ishii T, Katanuma A, Toyonaga H, Chikugo K, Nasuno H, Kin T, Hayashi T, Takahashi K. Role of Endoscopic Ultrasound in the Diagnosis of Pancreatic Neuroendocrine Neoplasms. Diagnostics (Basel) 2021;11:316. [PMID: 33672085 DOI: 10.3390/diagnostics11020316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]
9 Li Z, Du S, Feng W, Zhang W, Li G, Wei J, Zhang G, Zhao L. Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors. Eur J Gastroenterol Hepatol 2019;31:749-55. [PMID: 30601340 DOI: 10.1097/MEG.0000000000001350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Masui T, Nagai K, Anazawa T, Kasai Y, Sato A, Nakano K, Uchida Y, Yogo A, Kawaguchi Y, Takaori K, Uemoto S. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection? Scand J Gastroenterol 2020;55:479-84. [PMID: 32223573 DOI: 10.1080/00365521.2020.1743352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Albers MB, Manoharan J, Bartsch DK. Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1. Best Pract Res Clin Endocrinol Metab 2019;33:101318. [PMID: 31521501 DOI: 10.1016/j.beem.2019.101318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Albers MB, Manoharan J, Bollmann C, Chlosta MP, Holzer K, Bartsch DK. Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1. World J Surg. 2019;43:552-558. [PMID: 30288555 DOI: 10.1007/s00268-018-4809-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
14 Wu W, Jin G, Li H, Miao Y, Wang C, Liang T, Ou J, Zhao Y, Yuan C, Li Y, Lou W, Wu Z, Qin R, Wang H, Hao J, Yu X, Huang H, Tan G, Liu X, Xu K, Wang L, Yang Y, Hao C, Wang W, Guo K, Wei J, Wang Y, Peng C, Wang X, Cai S, Jiang J, Wu X, Yu X, Li F, Zhao Y. The current surgical treatment of pancreatic neuroendocrine neoplasms in China: a national wide cross-sectional study. Journal of Pancreatology 2019;2:35-42. [DOI: 10.1097/jp9.0000000000000019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
15 Hamano Y, Moriwaki T, To K, Watahiki T, Yamada T, Sakashita S, Hyodo I. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression. Intern Med 2019;58:1087-91. [PMID: 30568142 DOI: 10.2169/internalmedicine.1809-18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Hwang HS, Kim Y, An S, Kim SJ, Kim JY, Kim SY, Hwang DW, Park DH, Lee SS, Kim SC, Seo DW, Hong SM. Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated. Pancreas 2018;47:1296-303. [PMID: 30211805 DOI: 10.1097/MPA.0000000000001157] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
17 Zhuge X, Guo C, Chen Y, Feng L, Jia R, Zhao Y, Sun K, Wang Z, Chen X. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. Pancreas 2018;47:1290-5. [DOI: 10.1097/mpa.0000000000001181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Guo C, Zhuge X, Wang Q, Xiao W, Wang Z, Wang Z, Feng Z, Chen X. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. Cancer Imaging. 2018;18:37. [PMID: 30333055 DOI: 10.1186/s40644-018-0170-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
19 Hijioka S, Sakuma K, Aoki M, Mizuno N, Kuwahara T, Okuno N, Hara K, Yatabe Y. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother Pharmacol 2019;83:43-52. [PMID: 30310970 DOI: 10.1007/s00280-018-3700-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
21 Guo C, Chen X, Wang Z, Xiao W, Wang Q, Sun K, Zhuge X. Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. Oncotarget 2017;8:42962-73. [PMID: 28487490 DOI: 10.18632/oncotarget.17309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
22 Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kuwahara T, Yamamura T, Funasaka K, Nakamura M, Miyahara R, Ishigami M, Watanabe O, Hashimoto S, Hirakawa A, Ratanachu-Ek T, Goto H. Endoscopic ultrasound in diagnosis of solid pancreatic lesions: Elastography or contrast-enhanced harmonic alone vs the combination. Endosc Int Open. 2017;5:E1136-E1143. [PMID: 29124123 DOI: 10.1055/s-0043-118829] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
23 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
24 Miki M, Ito T, Hijioka M, Lee L, Yasunaga K, Ueda K, Fujiyama T, Tachibana Y, Kawabe K, Jensen RT, Ogawa Y. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. Jpn J Clin Oncol 2017;47:520-8. [PMID: 28334992 DOI: 10.1093/jjco/hyx032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
25 Ueda K, Ito T, Kawabe K, Lee L, Fujiyama T, Tachibana Y, Miki M, Yasunaga K, Takaoka T, Nishie A, Asayama Y, T Jensen R, Ogawa Y. Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization Be Evaluated at 60 or 120 Seconds? Intern Med 2017;56:2985-91. [PMID: 28943589 DOI: 10.2169/internalmedicine.9107-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li Y, Simonds WF. Recent advances in the management of endocrine malignancies associated with hereditary hyperparathyroidism syndromes. International Journal of Endocrine Oncology 2017;4:85-102. [DOI: 10.2217/ije-2016-0018] [Reference Citation Analysis]
27 Guo C, Chen X, Xiao W, Wang Q, Sun K, Wang Z. Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. Onco Targets Ther 2017;10:1465-74. [PMID: 28331340 DOI: 10.2147/OTT.S127803] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]